Acute promyelocytic leukemia: Evolving therapeutic strategies

Blood

Volumn 99, Issue 3, 2002, Pages 759-767

  Tallman, Martin S ^a,b,c   Nabhan, Chadi ^a,b,c   Feusner, James H ^a,b,c   Rowe, Jacob M ^a,b,c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b CHILDREN S HOSPITAL OAKLAND   (United States)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ARSENIC TRIOXIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; IDARUBICIN; MITOXANTRONE; PREDNISOLONE; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; BLOOD CLOTTING DISORDER; DRUG MIXTURE; GENE INDUCTION; HUMAN; LEUKEMIA REMISSION; LIVER TOXICITY; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; RELAPSE; RETINOIC ACID SYNDROME; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; STEM CELL TRANSPLANTATION;

EID: 0036464594     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.3.759     Document Type: Review

References (121)

1. Significantly lower P-glycoprotein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia: Immunological, molecular and functional analyses
2. P-glycoprotein (PGP), lung resistance-related protein (LRP) and multidrug resistance-associated protein (MRP) expression in acute promyelocytic leukaemia
3. Role of P-glycoprotein in all-trans retinoic acid (ATRA) resistance in acute promyelocytic leukaemia cells: Analysis of intracellular concentration of ATRA
4. Acute promyelocytic leukemia: Results of treatment by daunorubicin
5. Acute promyelocytic leukemia: Management of the coagulopathy during daunorubicin-prednisone remission induction
6. Acute promyelocytic leukemia: Retrospective study of 119 patients treated with daunorubicin
7. Acute promyelocytic leukemia: Clinical aspects and results of treatment in 62 patients
8. Acute promyelocytic leukemia: Therapy results and prognostic factors
9. Idarubicin (4-demethoxydaunorubicin) as single agent for remission induction of previously untreated acute promyelocytic leukemia: A pilot study of the Italian cooperative group GIMEMA
10. Event-free survival (EFS) duration in newly diagnosed acute promyelocytic leukemia (APL) is favorably influenced by induction treatment with idarubicin alone: Final results of the GIMEMA randomized study (LAP389) comparing idarubicin+Ara-C in newly diagnosed APL
11. Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia
12. Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine
13. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: A Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study
14. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RAR-alpha-positive acute promyelocytic leukemia
15. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy
16. A randomized trial of amsacrine and rubidazone in 39 patients with acute promyelocytic leukemia
17. Prognostic analysis of patients with acute promyelocytic leukemia
18. Use of all-trans retinoic acid in the treatment of APL
19. A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients
20. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results
21. Retinoic acids in the treatment of acute promyelocytic leukemia
22. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid)
23. All-trans-retinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: A pilot study on 26 cases
24. Effect of all trans-retinoic acid in newly diagnosed acute promyelocytic leukemia: Results of a multicenter randomized trial
25. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: Impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with alltrans retinoic acid
26. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome
27. Incidence, clinical features, and outcome of all transretinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia
28. A randomized comparison of all trans-retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia
29. All-trans-retinoic acid in acute promyelocytic leukemia
30. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: Result of the Randomized MRC Trial
31. Double induction strategy including high-dose cytarabine in combination with all-trans retinoic acid: Effects in patients with newly diagnosed acute promyelocytic leukemia
32. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy
33. Uncertainties in the standard care of acute myelogenous leukemia
34. Molecular evaluation of response to all-trans-retinoic acid therapy in patients with acute promyelocytic leukemia
35. Minimal residual disease detection in acute promyelocytic leukemia by reverse-transcriptase PCR: Evaluation of PML-RAR alpha and RAR alpha-PML assessment in patients who ultimately relapse
36. Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor alpha clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia
37. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RAR-alpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial
38. Role of maintenance chemotherapy in acute promyelocytic leukemia
39. Treatment of acute promyelocytic leukemia: A report of 70 cases
40. All-trans retinoic acid in acute promyelocytic leukemia: Long-term outcome results and prognostic factor analysis from Intergroup protocol 0129
41. All-trans retinoic acid for acute promyelocytic leukemia: Results of the New York Study
42. Aida Protocol: The Italian way of treating APL
43. Reduction of pulmonary toxicity by prednisolone prophylaxis during all-trans retinoic acid treatment of acute promyelocytic leukemia
44. A phase II study of all-trans retinoic acid (ATRA) with prednisone prophylaxis in the treatment of acute promyelocytic leukemia (APL)
45. Dexamethasone does not counteract the response of acute promyelocytic leukaemia cells to all-trans retinoic acid
46. Extramedullary relapse after all-trans retinoic acid treatment in acute promyelocytic leukemia - The occurrence of retinoic acid syndrome is a risk factor
47. Two cases of extramedullary acute promyelocytic leukemia: Cytogenetics, molecular biology, and phenotypic and clinical studies
48. Extramedullary acute promyelocytic leukemia
49. Extramedullary involvement in patients with acute promyelocytic leukemia: A report of seven cases
50. Extramedullary disease in acute promyelocytic leukemia
51. Incidence and outcome of central nervous system (CNS) relapses in acute promyelocytic leukemia (APL) treated with all-trans retinoic acid (ATRA) and chemotherapy (CT)
52. All-trans retinoic acid regulates adhesion mechanism and transmigration of the acute promyelocytic leukemia cell line NB-4 under physiologic flow
53. Reverse transcription-polymerase chain reaction for PML-RAR alpha fusion transcripts in acute promyelocytic leukemia and its application to minimal residual leukemia detection
54. Prognostic significance of the RT-PCR assay of PML-RARA transcripts in acute promyelocytic leukemia
55. High frequency of acute promyelocytic leukemia among Latinos with acute myeloid leukemia
56. Therapy of molecular relapse in acute promyelocytic leukemia
57. High-dose cytarabine therapy induces a molecular remission in APL patients who failed to achieve a complete response following treatment with ATRA and anthracyclines
58. Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia
59. Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR
60. Monitoring minimal residual disease and predicting relapse in APL by quantitating PML-RARα transcripts with a sensitive competitive RT-PCR method
61. A comparison of induction and maintenance therapy for acute nonlymphocytic leukemia in childhood: Results of a Pediatric Oncology Group study
62. Acute nonlymphocytic leukemias of childhood: Inter-observer variability and problems in the use of the FAB classification
63. Acute promyelocytic leukemia in children: Experience of the Italian Pediatric Hematology and Oncology Group (AIEOP)
64. Childhood acute promyelocytic leukemia: A rare variant of nonlymphoid leukemia with distinctive clinical and biologic features
65. Acute promyelocytic leukemia in childhood
66. Acute promyelocytic leukemia in children
67. Microgranular variant of acute promyelocytic leukemia in children
68. Clinical characteristics and treatment results of acute promyelocytic leukemia in children
69. Treatment results of intermittent and cyclic regimen with ATRA and chemotherapy in childhood acute promyelocytic leukemia
70. All-trans-retinoic acid (ATRA): Pediatric acute promyelocytic leukemia
71. Treatment with all-trans retinoic acid in acute promyelocytic leukemia reduces early deaths in children
72. Immunophenotype of adult and childhood acute promyelocytic leukaemia: Correlation with morphology, type of PML gene break-point and clinical outcome: A cooperative Italian study on 196 cases
73. Oral all-trans-retinoic acid administration in intubated patients with acute promyelocytic leukemia
74. Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia
75. Treatment of newly diagnosed and relapsed acute promyelocytic leukemia with intravenous liposomal all-trans retinoic acid
76. Treatment of newly-diagnosed acute promyelocytic leukemia with liposomal all-trans retinoic acid
77. Phase I and pharmacokinetic evaluation of all-trans-retinoic acid in pediatric patients with cancer
78. Tretinoin toxicity in children with acute promyelocytic leukaemia
79. Clinical and pharmacokinetic studies of all-trans-retinoic acid in pediatric patients with cancer
80. Increased risk of cardiac dysfunction after anthracyclines in girls
81. Anthracycline-induced cardiotoxicity in children with malignancies
82. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: The Pediatric Oncology Group experience
83. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion
84. Clinical and biological characteristics of acute promyelocytic leukemia in Taiwan: A high relapse rate in patients with high initial and peak white blood cell counts during all-trans retinoic acid treatment
85. The JALSG APL92 Study for newly diagnosed acute promyelocytic leukemia (APL): Analysis of prognostic factors to increase cure rate in the next study
86. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: A joint study of the PETHEMA and GIMEMA Cooperative groups
87. The role of all-trans-retinoic acid (ATRA) treatment in newly-diagnosed acute promyelocytic leukemia patients aged > 60 years
88. Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195
89. Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia
90. Treatment of acute promyelocytic leukemia by Ailing-1 therapy with use of syndrome differentiation of traditional Chinese medicine
91. Arsenic trioxide treated 72 cases of acute promyelocytic leukemia
92. Use of arsenic trioxide in the treatment of APL, clinical efficacy and pharmacokinetics in relapsed patients
93. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: Remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients
94. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins
95. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells
96. 3 exerts dose-dependent dual effects on APL cells
97. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway
98. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide
99. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia
100. Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated arsenic trioxide
101. Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide
102. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide
103. Arsenic trioxide in the treatment of a patient with multiply recurrent, ATRA-resistant promyelocytic leukemia: A case report
104. Clinical observation on arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia
105. Combined effects of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo
106. 3) ± all-trans retinoic acid (ATRA): The French As98 Study
107. Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: A comparison with conventional dosage
108. European survey of bone marrow transplantation in acute promyelocytic leukemia (M3)
109. Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: Prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RAR alpha fusion gene
110. Stem cell transplantation (SCT) for acute promyelocytic leukemia (APL) in the ATRA era: A survey of the European Blood and Marrow Transplantation Group (EBMT)
111. The role of stem cell transplantation in acute promyelocytic leukemia
112. The short form of PML-RAR-alpha fusion transcript is associated with poor survival
113. Isoforms of PML-retinoic acid receptor alpha fused transcripts affect neither clinical features of acute promyelocytic leukemia nor prognosis after treatment with all-trans retinoic acid
114. Association of PML-RAR alpha fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: An intergroup molecular study
115. Molecular analysis and clinical outcome of adult APL patients with the type V PML-RAR-alpha isoform: Results from intergroup protocol 0129
116. CD56 expression in acute promyelocytic leukemia: A possible indicator of poor treatment outcome?
117. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy
118. Additional chromosome abnormalities confer worse prognosis in acute promyelocytic leukaemia
119. Secondary cytogenetic changes in acute promyelocytic leukemia - Prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: A Cancer and Leukemia Group B study
120. HLA class I in acute promyelocytic leukemia (APL): Possible correlation with clinical outcome
121. Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibodies M195